TNF and melanoma: Moreover, comparing the evolution of the plasma sphingolipidome between patients enrolled in the TICIMEL and MELANFα clinical trials showed that anti-TNF reduced the production of monohexosylceramides in plasma, further supporting that TNF-dependent signaling contributes to glycosphingolipid accumulation in the context of ICI therapy in advanced melanoma patients.